Biofrontera Inc. (BFRIW) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
Analysten schätzen Gewinn pro Aktie (EPS) von $-3.04 und Umsatz von $0.04B für das nächste Geschäftsjahr.
Gewinn pro Aktie (EPS) Erfolgsbilanz: 2024: tatsächlich $0.00 vs Schätzung $-3.04 (übertroffen +99.9%). 2025: tatsächlich $-1.04 vs Schätzung $-1.39 (übertroffen +25.2%). Analysten-Genauigkeit: 0%.
GpA-Schätzungen — BFRIW
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.00
vs Est –$3.04
▲ 94,743.8% off
2025
Actual –$1.04
vs Est –$1.39
▲ 33.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Umsatzschätzungen — BFRIW
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.037B
vs Est $0.039B
▼ 5.4% off
2025
Actual $0.042B
vs Est $0.041B
▲ 2.3% off
Revenue Trend
Moderate revenue growth trend. Analysts expect stable revenue going forward.
